Legal Representation
Attorney
Austin Padgett
USPTO Deadlines
Application History
18 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 10, 2018 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 10, 2018 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| May 9, 2018 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 7, 2018 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 7, 2018 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 7, 2018 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 25, 2017 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Oct 23, 2017 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 23, 2017 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Oct 23, 2017 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 9, 2017 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 14, 2017 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 14, 2017 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 22, 2017 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 3, 2017 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 27, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 25, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 22, 2016 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; medicines for human and veterinary purposes, namely, medicines for the treatment of substance use disorders, substance dependence, substance withdrawal, substance addiction, and substance overdose, for the treatment of co-morbidities associated with substance use disorders, for the treatment of mental health diseases and disorders, for the treatment of central nervous system diseases and disorders, and for the treatment of pain; Pharmaceutical preparations for use in the treatment of chemical addictions
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005